| scholarly article | Q13442814 |
| P50 | author | Michael P. Snyder | Q28924918 |
| P2093 | author name string | Kun-Hsing Yu | |
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| Predictive biomarkers: a paradigm shift towards personalized cancer medicine | Q37921593 | ||
| Personalized cancer medicine and the future of pathology. | Q37965048 | ||
| Principles and methods of integrative genomic analyses in cancer | Q38206642 | ||
| A genomics-based classification of human lung tumors | Q39123357 | ||
| Vascular invasion in non-small cell lung carcinoma | Q39403021 | ||
| The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours | Q39512984 | ||
| Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsets | Q39617870 | ||
| Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). | Q39907905 | ||
| ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare | Q39923537 | ||
| Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer. | Q40155442 | ||
| MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations | Q42731321 | ||
| Potential of human saliva for nuclear magnetic resonance-based metabolomics and for health-related biomarker identification | Q43271462 | ||
| Blood vessel invasion and expression of sialyl Lewisx and proliferating cell nuclear antigen in stage I non-small cell lung cancer. Relation to postoperative recurrence | Q50775156 | ||
| Serine, but not glycine, supports one-carbon metabolism and proliferation of cancer cells. | Q53052028 | ||
| Chipping away at the lung cancer genome | Q54525027 | ||
| A Prognostic DNA Methylation Signature for Stage I Non–Small-Cell Lung Cancer | Q57239837 | ||
| Fractals and cancer | Q74087944 | ||
| Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features | Q77626785 | ||
| Identification of possible biomarkers for breast cancer from free fatty acid profiles determined by GC–MS and multivariate statistical analysis | Q82394446 | ||
| A novel grading system for clear cell renal cell carcinoma incorporating tumor necrosis | Q85952835 | ||
| Deep RNA sequencing analysis of readthrough gene fusions in human prostate adenocarcinoma and reference samples | Q21092937 | ||
| Cancer as an evolutionary and ecological process | Q22122026 | ||
| Cancer genome landscapes | Q22242276 | ||
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands | Q24562877 | ||
| HMDB 3.0--The Human Metabolome Database in 2013 | Q24595162 | ||
| Differential oestrogen receptor binding is associated with clinical outcome in breast cancer | Q24595511 | ||
| RNA-Seq: a revolutionary tool for transcriptomics | Q24596169 | ||
| Understanding the Warburg effect: the metabolic requirements of cell proliferation | Q24604760 | ||
| The Cancer Genome Atlas Pan-Cancer analysis project | Q24606808 | ||
| Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis | Q24607308 | ||
| Integrative analysis of the melanoma transcriptome | Q24608060 | ||
| RNA-seq: an assessment of technical reproducibility and comparison with gene expression arrays | Q24655562 | ||
| Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance | Q26866517 | ||
| Toward Precision Medicine | Q27021937 | ||
| Single molecule and single cell epigenomics. | Q27026725 | ||
| EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy | Q27824812 | ||
| Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. | Q27852316 | ||
| Global cancer statistics, 2012 | Q27860501 | ||
| Cancer statistics, 2015 | Q27860576 | ||
| Chromatin modifications and their function | Q27861067 | ||
| Metabolomics reviewed: a new "omics" platform technology for systems biology and implications for natural products research. | Q36353799 | ||
| Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study | Q36395796 | ||
| Microarray analysis and tumor classification | Q36499716 | ||
| Machine learning in bioinformatics | Q36500313 | ||
| Metabolomics technology and bioinformatics | Q36505958 | ||
| A new genome-driven integrated classification of breast cancer and its implications | Q36664694 | ||
| Translating insights from the cancer genome into clinical practice | Q37127235 | ||
| Global levels of histone modifications predict prognosis in different cancers | Q37164151 | ||
| Epigenetic changes in cancer | Q37288845 | ||
| Gene-expression-based prognostic assays for breast cancer | Q37741797 | ||
| Immunologic biomarkers as correlates of clinical response to cancer immunotherapy | Q37827418 | ||
| Molecular classification of cancer: class discovery and class prediction by gene expression monitoring | Q27861072 | ||
| Mass spectrometry-based proteomics | Q28182890 | ||
| Proteogenomic characterization of human colon and rectal cancer | Q28244320 | ||
| Comparison of network-based pathway analysis methods | Q28274818 | ||
| Vemurafenib: the first drug approved for BRAF-mutant cancer | Q28276886 | ||
| Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal | Q28288215 | ||
| Mapping of transcription factor binding regions in mammalian cells by ChIP: comparison of array- and sequencing-based technologies | Q28306149 | ||
| Knowledge Discovery and interactive Data Mining in Bioinformatics--State-of-the-Art, future challenges and research directions | Q28654387 | ||
| Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer | Q29547564 | ||
| Gene-expression profiles predict survival of patients with lung adenocarcinoma | Q29614443 | ||
| Personal omics profiling reveals dynamic molecular and medical phenotypes | Q29614800 | ||
| ChIP-seq: advantages and challenges of a maturing technology | Q29615336 | ||
| Cancer immunotherapy via dendritic cells | Q29615444 | ||
| Ten years of pathway analysis: current approaches and outstanding challenges | Q29615564 | ||
| A new initiative on precision medicine | Q29615654 | ||
| The role of DNA methylation in mammalian epigenetics | Q29617979 | ||
| RNA sequencing: advances, challenges and opportunities | Q29619605 | ||
| Cancer immunotherapy comes of age | Q29619918 | ||
| From genomics to proteomics | Q30482453 | ||
| International Cancer Genome Consortium Data Portal--a one-stop shop for cancer genomics data | Q30485151 | ||
| Transcriptional data: a new gateway to drug repositioning? | Q30557854 | ||
| Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets | Q30607290 | ||
| Predictive data mining in clinical medicine: current issues and guidelines | Q31088253 | ||
| Mass spectrometry and protein analysis | Q33239890 | ||
| Reverse-phase protein lysate microarrays for cell signaling analysis | Q33381529 | ||
| An integrative -omics approach to identify functional sub-networks in human colorectal cancer | Q33525505 | ||
| Visualization of omics data for systems biology | Q33535721 | ||
| The biology of ovarian cancer: new opportunities for translation | Q33622369 | ||
| Tumor heterogeneity: causes and consequences | Q33624298 | ||
| RET fusion gene: translation to personalized lung cancer therapy | Q33711282 | ||
| Bayesian approach to transforming public gene expression repositories into disease diagnosis databases | Q33859264 | ||
| Towards proteome standards: the use of absolute quantitation in high-throughput biomarker discovery | Q33912503 | ||
| The current state of chromatin immunoprecipitation | Q34092981 | ||
| Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. | Q34132010 | ||
| New driver mutations in non-small-cell lung cancer | Q34161395 | ||
| Criteria for the use of omics-based predictors in clinical trials | Q34269875 | ||
| Targeting MET Amplification as a New Oncogenic Driver. | Q34309927 | ||
| Tumour heterogeneity in the clinic | Q34372080 | ||
| When tissue antigens and antibodies get along: revisiting the technical aspects of immunohistochemistry--the red, brown, and blue technique | Q34377983 | ||
| NMR and pattern recognition methods in metabolomics: from data acquisition to biomarker discovery: a review | Q34444673 | ||
| Neoantigens in cancer immunotherapy. | Q34470074 | ||
| The precision medicine initiative: a new national effort | Q34474452 | ||
| Microarray and histopathological analysis of tumours: the future and the past? | Q34572102 | ||
| Metabolomics: available results, current research projects in breast cancer, and future applications. | Q34628323 | ||
| Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia | Q34630212 | ||
| Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts | Q34714204 | ||
| Identification of fusion genes in breast cancer by paired-end RNA-sequencing | Q34964405 | ||
| OMICS-based personalized oncology: if it is worth doing, it is worth doing well! | Q35042467 | ||
| Prioritization of cancer marker candidates based on the immunohistochemistry staining images deposited in the human protein atlas | Q35058538 | ||
| Emerging landscape of oncogenic signatures across human cancers | Q35058708 | ||
| Bioinformatics tools for cancer metabolomics | Q35163111 | ||
| Methods and applications of antibody microarrays in cancer research | Q35574629 | ||
| Personalized genomic analyses for cancer mutation discovery and interpretation | Q35602861 | ||
| ChIP-chip: considerations for the design, analysis, and application of genome-wide chromatin immunoprecipitation experiments | Q35676599 | ||
| Translating cancer 'omics' to improved outcomes | Q35694365 | ||
| Genome-scale analysis of aberrant DNA methylation in colorectal cancer | Q35694387 | ||
| ROS1 rearrangements in lung adenocarcinoma: prognostic impact, therapeutic options and genetic variability | Q35833066 | ||
| Targeted cancer therapy | Q35953128 | ||
| Protein microarrays as tools for functional proteomics | Q36034993 | ||
| The future of genomics in pathology | Q36082163 | ||
| Genetic Changes in Squamous Cell Lung Cancer: A Review | Q36115735 | ||
| Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review | Q36147654 | ||
| A Functional Copy-Number Variation in MAPKAPK2 Predicts Risk and Prognosis of Lung Cancer | Q36152896 | ||
| Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing | Q36256943 | ||
| P433 | issue | 8 | |
| P304 | page(s) | 2525-2536 | |
| P577 | publication date | 2016-04-20 | |
| P1433 | published in | Molecular & Cellular Proteomics | Q6895932 |
| P1476 | title | Omics Profiling in Precision Oncology | |
| P478 | volume | 15 |
| Q50104991 | A roadmap towards personalized immunology. |
| Q51173657 | An integrated analysis identifies STAT4 as a key regulator of ovarian cancer metastasis |
| Q39426287 | Application of metabolomics in sarcoma: From biomarkers to therapeutic targets |
| Q57113927 | Applications of RNA Indexes for Precision Oncology in Breast Cancer |
| Q90254268 | Artificial intelligence in healthcare |
| Q45943784 | Association of Omics Features with Histopathology Patterns in Lung Adenocarcinoma. |
| Q92252361 | Autoimmune Effects of Lung Cancer Immunotherapy Revealed by Data-Driven Analysis on a Nationwide Cohort |
| Q62489264 | Computational Approaches in Theranostics: Mining and Predicting Cancer Data |
| Q50006534 | DNA-Targeted Precision Medicine; Have we Been Caught Sleeping? |
| Q41603225 | Exploitation of Gene Expression and Cancer Biomarkers in Paving the Path to Era of Personalized Medicine. |
| Q55402211 | Expression and network analysis of YBX1 interactors for identification of new drug targets in lung adenocarcinoma. |
| Q52373176 | Integrative omics for health and disease |
| Q28069660 | Metabolomics of Head and Neck Cancer: A Mini-Review |
| Q58569259 | Modified SureSelect Target Enrichment Protocol for Illumina Multiplexed Sequencing of FFPE Samples |
| Q45945277 | Omics AnalySIs System for PRecision Oncology (OASISPRO): A Web-based Omics Analysis Tool for Clinical Phenotype Prediction. |
| Q90355689 | Omics-based insights into therapy failure of pediatric B-lineage acute lymphoblastic leukemia |
| Q36396606 | Precision oncology based on omics data: The NCT Heidelberg experience |
| Q26741336 | Precision or Personalized Medicine for Cancer Chemotherapy: Is there a Role for Herbal Medicine |
| Q37188409 | Predicting non-small cell lung cancer prognosis by fully automated microscopic pathology image features |
| Q93166932 | Quantitative SWATH-Based Proteomic Profiling for Identification of Mechanism-Driven Diagnostic Biomarkers Conferring in the Progression of Metastatic Prostate Cancer |
| Q36264188 | Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions. |
Search more.